These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Safety of Proton Pump Inhibitors Questioned Based on a Large Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Simin J; Liu Q; Fornes R; Brusselaers N Gastroenterology; 2020 Mar; 158(4):1172-1173. PubMed ID: 31836528 [No Abstract] [Full Text] [Related]
4. What Is the Optimal Follow-up Time to Ascertain the Safety of Proton Pump Inhibitors? Losurdo G; Di Leo A; Leandro G Gastroenterology; 2020 Mar; 158(4):1175. PubMed ID: 31884072 [No Abstract] [Full Text] [Related]
5. Proton Pump Inhibitor Therapy and Fracture Risk: Discrepancy of Results Between Observational and Interventional Studies. Sugiyama T Gastroenterology; 2020 Mar; 158(4):1174. PubMed ID: 31982411 [No Abstract] [Full Text] [Related]
6. Association between the use of proton pump inhibitors and cardiovascular events: A note of caution. Raschi E; Bianchin M; Poluzzi E; De Ponti F Neurogastroenterol Motil; 2017 Feb; 29(2):. PubMed ID: 28132439 [No Abstract] [Full Text] [Related]
7. The prevalence of risk factors for gastrointestinal complications and use of gastroprotection among persons hospitalized for cardiovascular disease. Targownik LE; Al-Mamfud A Aliment Pharmacol Ther; 2006 Mar; 23(6):743-9. PubMed ID: 16556176 [TBL] [Abstract][Full Text] [Related]
8. [Comment. Higher safety for patients and lower costs for society]. García-Altés A Gac Sanit; 2006; 20(1):58. PubMed ID: 16539995 [No Abstract] [Full Text] [Related]
9. Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin. Gesheff MG; Franzese CJ; Bliden KP; Contino CJ; Rafeedheen R; Tantry US; Gurbel PA Expert Rev Clin Pharmacol; 2014 Sep; 7(5):645-53. PubMed ID: 25098174 [TBL] [Abstract][Full Text] [Related]
10. Reply. Moayyedi P; Eikelboom J; Yusuf S Gastroenterology; 2020 Mar; 158(4):1175-1176. PubMed ID: 31917257 [No Abstract] [Full Text] [Related]
11. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Pilotto A; Franceschi M; Leandro G; Paris F; Cascavilla L; Longo MG; Niro V; Andriulli A; Scarcelli C; Di Mario F Aliment Pharmacol Ther; 2004 Nov; 20(10):1091-7. PubMed ID: 15569111 [TBL] [Abstract][Full Text] [Related]
12. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Moayyedi P; Eikelboom JW; Bosch J; Connolly SJ; Dyal L; Shestakovska O; Leong D; Anand SS; Störk S; Branch KRH; Bhatt DL; Verhamme PB; O'Donnell M; Maggioni AP; Lonn EM; Piegas LS; Ertl G; Keltai M; Cook Bruns N; Muehlhofer E; Dagenais GR; Kim JH; Hori M; Steg PG; Hart RG; Diaz R; Alings M; Widimsky P; Avezum A; Probstfield J; Zhu J; Liang Y; Lopez-Jaramillo P; Kakkar A; Parkhomenko AN; Ryden L; Pogosova N; Dans A; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik T; Vinereanu D; Tonkin AM; Lewis BS; Felix C; Yusoff K; Metsarinne K; Fox KAA; Yusuf S; Gastroenterology; 2019 Aug; 157(2):403-412.e5. PubMed ID: 31054846 [TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors and chronic kidney disease: Reevaluating the evidence from a randomized controlled trial. Gerstman BB Pharmacoepidemiol Drug Saf; 2021 Jan; 30(1):4-8. PubMed ID: 32909330 [No Abstract] [Full Text] [Related]
14. Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery? Ziegelin M; Hoschtitzky A; Dunning J; Hooper T Interact Cardiovasc Thorac Surg; 2007 Aug; 6(4):534-7. PubMed ID: 17669930 [TBL] [Abstract][Full Text] [Related]
15. The contribution of clinical and pathological predisposing factors to severe gastro-duodenal lesions in patients with long-term low-dose aspirin and proton pump inhibitor therapy. Negovan A; Iancu M; Moldovan V; Sàrkàny K; Bataga S; Mocan S; Țilea I; Banescu C Eur J Intern Med; 2017 Oct; 44():62-66. PubMed ID: 28576397 [TBL] [Abstract][Full Text] [Related]
16. The choice of a proton pump inhibitor. Schaffalitzky de Muckadell OB Basic Clin Pharmacol Toxicol; 2004 Mar; 94(3):105. PubMed ID: 15049338 [No Abstract] [Full Text] [Related]
17. Long-term proton pump inhibitor use after Kobayashi J; Uchida H; Ito J Gut; 2019 Jun; 68(6):1131. PubMed ID: 29802173 [No Abstract] [Full Text] [Related]
18. Aspirin and omeprazole for secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers. García-Rayado G; Sostres C; Lanas A Expert Rev Clin Pharmacol; 2017 Aug; 10(8):875-888. PubMed ID: 28463532 [TBL] [Abstract][Full Text] [Related]
19. Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Freston JW Am J Gastroenterol; 1997 Apr; 92(4 Suppl):51S-55S; discussion 55S-57S. PubMed ID: 9127627 [TBL] [Abstract][Full Text] [Related]
20. Systematic review: Rebound acid hypersecretion after therapy with proton pump inhibitors. Hunfeld NG; Geus WP; Kuipers EJ Aliment Pharmacol Ther; 2007 Jan; 25(1):39-46. PubMed ID: 17229219 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]